Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America

TLDR

Since 2004, new antifungal agents and studies on candidemia, invasive candidiasis, and mucosal disease—including prevention in high‑risk neonates and adults—have emerged. The guidelines aim to replace the 2004 edition and provide updated recommendations for clinicians treating or at risk of invasive and mucosal candidiasis. An expert panel from the Infectious Diseases Society of America developed the guidelines, incorporating new evidence into the revised document.

Abstract

Abstract Guidelines for the management of patients with invasive candidiasis and mucosal candidiasis were prepared by an Expert Panel of the Infectious Diseases Society of America. These updated guidelines replace the previous guidelines published in the 15 January 2004 issue of Clinical Infectious Diseases and are intended for use by health care providers who care for patients who either have or are at risk of these infections. Since 2004, several new antifungal agents have become available, and several new studies have been published relating to the treatment of candidemia, other forms of invasive candidiasis, and mucosal disease, including oropharyngeal and esophageal candidiasis. There are also recent prospective data on the prevention of invasive candidiasis in high-risk neonates and adults and on the empiric treatment of suspected invasive candidiasis in adults. This new information is incorporated into this revised document.